Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
ACTOnco®+ comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.
Identify More Evidence-Based Treatment Options
ACT Genomics panels are designed to support physicians with evidence-based and actionable insights to answer clinical challenges in cancer management. Identifying the genetic alterations harbored in the patient’s tumor and understanding how they affect cancer-related cell signaling pathways to drive tumor growth are the keys to finding suitable treatment strategies for each patient.
Comprehensive Genomic Profiling
BRCA1/2&DNA Repair Gene Testing
Real-Time Monitoring with Liquid Biopsy
ACTMonitor® + uses circulating tumor DNA (ctDNA) to provide an early detection of cancer recurrence and drug resistance. ctDNA consists of fragments of DNA released from necrotic or apoptotic tumor cells into the blood stream. ACTMonitor® + detects the occurrence of variants that would lead to drug sensitivity or resistance, allowing assessment of treatment responses before changes can be observed by protein markers and in radioimages.
Cancer Monitoring
Real-time monitoring through blood specimen
Detects drug resistance
Assesses treatment responses
Identify High Risk Groups for Hereditary Cancer
Approximately 5-10% of cancers are caused by germline mutations. In addition to the well-characterized BRCA1/2, mutations in many other genes also cause a higher lifetime risk of cancer, up to 10-90 times higher than for someone without a mutation.
ACTRisk™ is a genetic test that analyzes 32 genes strongly associated with common hereditary cancers. It provides important genetic information that helps physicians and genetic counselors to precisely evaluate cancer risk and discuss risk management options with clients.
Promising treatment outcome of molecular matched therapy in advanced salivary gland carcinoma 2020-03-23
In a phase IIa study (MyPathway), advanced salivary gland carcinoma were treated with molecular matched therapy based on their molecular characteristics, and the results showed a promising efficacy.
Neratinib plus fulvestrant showed promising anti-tumor activities in patients with HER2-mutant breast cancer 2020-03-23
HER2 mutation is one of the acquired resistance mechanisms in breast cancer. In a phase II SUMMIT study, HER2-mutant breast cancers were sensitive to neratinib treatment. Besides, the resistance mechanisms of neratinib were also studied.
FDA grants breakthrough therapy designation to JNJ-6372 in non-small cell lung cancer 2020-03-23
The FDA granted breakthrough therapy designation to JNJ-6372, an EGFR-mesenchymal epithelial transition factor (MET) bispecific antibody, to treat metastastic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.
Genetic testing results revealed the resistance mechanisms of DNA-damaging therapies in breast cancer 2020-02-27
Homologous recombination restoration, including reversion and nonreversion mechanisms in BRCA1/2 will cause drug resistance in BRCA1/2-mutation breast cancer patients who received PARP inhibitors or platinum chemotherapy as study shows.
Combination of cobimetinib and vemurafenib showed great anti-tumor activities in CRC patients with a BRAF V600E mutation 2020-02-27
In a phase II basket trial (TAPUR), cobimetinib and vemurafenib were used in combination to treat CRC patients with BRAF V600E mutations. This combination showed evidence of anti-tumor activities in this study.
Talazoparib demonstrated clinical activity in men with DNA damage repair mutations and metastatic castration-resistant prostate cancer 2020-02-27
In a phase II trial (TALAPRO-1), talazoparib demonstrated encouraging antitumor activity in metastatic castration-resistant prostate cancer with DNA damage repair mutations.
Step 1.
We are highly experienced and possess professional high standard procedures in the challenging process of retrieving DNA from FFPE samples for sequencing. Our scientists have optimized the methodology to consistently achieve successful sequencing with highly accurate results. In addition to FFPE samples, our platform also works with core needle biopsies, pleural effusion, ascites, blood samples, and buccal swaps.
Step 2.
ACT Genomics has established a state-of-the-art next generation sequencing (NGS) platform. Sequencing is performed on Ion Personal Genome Machines, Ion Proton sequencers and Illumina MiSeq; ACT Genomics is an Ion Torrent™ Certified Service Provider.
Step 3.
ACT Genomics integrates advanced annotation and visualization tools, coupled with public and proprietary databases to deliver comprehensive and comprehensible reports.
Step 4.
With accurate genomic profiling, visualizing genes with alterations in known cancer pathways and providing potential matching cancer targeted treatments from FDA and National Comprehensive Cancer Network (NCCN) guidelines, mutated sub-network in known pathways, as well as references, ACT Genomics aims to deliver a concise, reliable and actionable meaningful clinical report.
